Acitrin-L

 2.5 mg/5 ml Oral Solution
ACI Limited

60 ml bottle: ৳ 55.00

Share this page
Indications

Approved Indications 

- Seasonal Allergic Rhinitis: Provides relief from allergic rhinitis symptoms, including nasal and ocular symptoms. Clinical evidence supports its use in seasonal allergic rhinitis. The UK product information covers allergic rhinitis in adults and children aged 6 years and above. However, seasonal allergic rhinitis is not separately listed in the 2025 US FDA prescribing information. [1] [3] 

- Perennial Allergic Rhinitis: Provides relief from symptoms associated with perennial allergic rhinitis. The US FDA prescribing information specifically includes children aged 6 months to 2 years. The UK 5 mg tablet product information covers allergic rhinitis, including persistent allergic rhinitis, in adults and children aged 6 years and above. [1] [3] 

- Chronic Idiopathic Urticaria: Treatment of uncomplicated skin manifestations, including itching and wheals, associated with chronic idiopathic urticaria. Approved for adults and children aged 6 months and older under the cited US FDA prescribing information. The UK 5 mg tablet product information specifies adults and children aged 6 years and above. [1] [3] 

Clinically Accepted Off-Label / Adjunctive Uses 

- Atopic Dermatitis: Evidence in the established reference set is insufficient to support levocetirizine as a routinely recommended adjunctive treatment for atopic dermatitis-related itching. It should not be presented as an established clinically accepted off-label indication. Neither cited prescribing information lists atopic dermatitis as an indication. [1] [3] 

- Allergic Conjunctivitis: Oral antihistamines may help relieve ocular symptoms associated with allergic rhinitis. The 2024–2025 ARIA-EAACI guideline supports oral antihistamines for managing ocular symptoms in patients with allergic rhinitis. However, this is class-level evidence, not a separate levocetirizine-specific approval for standalone allergic conjunctivitis. [8]  

 

Dosage & Administration

Dosage and Administration 

Route: Oral (tablets or oral solution). 

Adults and Adolescents (≥12 years): 

  • 5 mg once daily in the evening. 

  • Some patients with chronic idiopathic urticaria may achieve adequate symptom control with 2.5 mg once daily. 

  • Maximum recommended dose: 5 mg daily. [1] [2] 

Children: 

  • 6–11 years: 2.5 mg once daily in the evening under the US FDA dosing recommendations. Do not exceed 2.5 mg daily. [1] 

  • 6 months–5 years: 1.25 mg once daily in the evening for chronic idiopathic urticaria, administered as oral solution (2.5 mL of 0.5 mg/mL solution). Do not exceed 1.25 mg daily. [1] 

Important age and indication restriction: 

  • For perennial allergic rhinitis, the US FDA prescribing information specifies the 1.25 mg dose for children aged 6 months–2 years. 

  • For chronic idiopathic urticaria, the recommended pediatric dosing extends from 6 months to 5 years at 1.25 mg daily and 6–11 years at 2.5 mg daily. [1] 

  • The UK SmPC specifies 5 mg once daily for children aged 6–12 years using its 5 mg tablet formulation. Therefore, pediatric dosing recommendations differ between international product labels. Do not combine these regimens or present one country's dosing as universal. [3] 

Elderly: 

  • Use with caution, particularly in patients with reduced renal function. 

  • No automatic dose reduction is required solely because of age; dose selection should consider renal function, comorbidities, and concomitant medications. 

  • Monitor renal function when clinically appropriate. [1] [3] 

Renal Impairment (CrCl-based adjustment): 

For adults and adolescents aged 12 years and older, the US FDA prescribing information recommends the following adjustments: 

 

Mechanism of Action (MOA)

Levocetirizine is the (R)-enantiomer of cetirizine and acts as a potent and selective antagonist of peripheral histamine H₁ receptors. It selectively blocks H₁-receptor activity, reducing histamine-mediated allergic responses, including itching, sneezing, rhinorrhea, and other symptoms of allergic rhinitis and urticaria. [1] [3] [4] 

Levocetirizine also demonstrates additional pharmacodynamic effects. In vitro studies show that it inhibits eotaxin-induced eosinophil migration. Experimental studies in humans have demonstrated reduced eosinophil recruitment, inhibition of VCAM-1 release, and modulation of vascular permeability during allergic reactions. These findings suggest additional anti-inflammatory activity, although their clinical significance is not fully established. [3] 

  • Levocetirizine is described as a peripheral H₁-receptor antagonist. However, human data on its penetration across the blood–brain barrier are not available in the cited product information. It may still cause drowsiness or somnolence; therefore, it should not be described as completely non-sedating. [1] [2] [3] 

 

Pharmacokinetics

- Absorption: Rapid and extensive oral absorption. The extent of absorption is dose-independent. Food does not affect overall drug exposure (AUC), although it may delay and reduce peak plasma concentrations. [2] [3] 

- Bioavailability: Absolute oral bioavailability is not specified in the established prescribing-information references. Therefore, the estimated value of approximately 100% should be removed unless supported by an appropriate pharmacokinetic study. [2] [3] 

- Tmax: Approximately 0.9 hours after oral tablet administration in adults. For oral solution, peak plasma concentrations occur at approximately 0.5 hours. A high-fat meal delays tablet Tmax by approximately 1.25 hours. [2]

- Distribution Volume (Vd): Approximately 0.4 L/kg, indicating a relatively restricted volume of distribution. [2] [3] 

- Protein Binding: Approximately 90–92% plasma protein-bound. [2] [3] 

- Metabolism: Minimal metabolism, with less than 14% of the administered dose undergoing metabolism. Metabolic pathways include aromatic oxidation, N- and O-dealkylation, and taurine conjugation. Dealkylation is primarily mediated by CYP3A4, whereas aromatic oxidation involves multiple or unidentified CYP isoforms. [2] [3] 

- Elimination Half-Life: Approximately 8–9 hours in healthy adults following oral tablet administration (mean 7.9 ± 1.9 hours). The half-life is shorter in young children.[2] [3] 

- Excretion: Approximately 85.4% of the administered dose is recovered through urinary excretion, including levocetirizine and its metabolites. Approximately 12.9% is excreted in feces. Renal elimination occurs through glomerular filtration and active tubular secretion. [2] [3] 

- Dialysis: Levocetirizine is poorly removed by hemodialysis. Less than 10% of the drug is removed during a standard 4-hour hemodialysis session. [2] [3] 

 

Pregnancy Category & Lactation
  • - Pregnancy: The FDA prescribing information does not assign levocetirizine an old pregnancy risk category (such as Category B). Available human data are insufficient to determine the risk of miscarriage, congenital abnormalities, or adverse maternal or fetal outcomes. Animal reproductive studies have shown no evidence of fetal harm at doses substantially higher than the maximum recommended human dose. According to the UK SmPC, levocetirizine may be considered during pregnancy when necessary. [1] [3] 

    - Lactation: Human milk data specific to levocetirizine are limited. Although its presence in human milk has not been directly established in the cited US prescribing information, cetirizine (the racemic parent compound) has been detected in human breast milk, and levocetirizine transfer into breast milk is considered likely. Adverse reactions may occur in breastfed infants; therefore, caution is recommended. [1] [3]

    - Recommendation: During pregnancy, consider levocetirizine only when clinically necessary after assessing potential benefits and risks. During breastfeeding, consider the mother's treatment needs, the benefits of breastfeeding, and potential adverse effects on the infant. Monitor the infant for possible adverse reactions. [1] [3]

     

Therapeutic Class
  • - Primary Class: Second-generation antihistamine with relatively low sedative potential. However, levocetirizine is not completely non-sedating and may cause drowsiness or somnolence. [1] [3] 

    - Subclass: Selective peripheral histamine H₁-receptor antagonist; pharmacologically classified among piperazine derivatives. [3] 

    - Enantiomer: The pharmacologically active (R)-enantiomer of cetirizine. [1] [2] [3] 

    - ATC Classification: R06AE09 – Levocetirizine. [3] 

     

Contraindications
  • - Known Hypersensitivity: Contraindicated in patients with known hypersensitivity to levocetirizine, cetirizine, or any ingredient of the formulation. The UK SmPC additionally lists hypersensitivity to hydroxyzine and other piperazine derivatives as a contraindication. [1] [2] [3] 

    - Severe Renal Impairment: Contraindicated in patients with end-stage renal disease (CrCl less than 10 mL/min) and those undergoing hemodialysis under the US FDA prescribing information. Levocetirizine is also contraindicated in children aged 6 months–11 years with renal impairment. The UK SmPC specifies end-stage renal disease requiring dialysis, with eGFR below 15 mL/min. [1] [2] [3] 

    - Certain Hereditary Carbohydrate Intolerance Conditions: Patients with rare hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take lactose-containing formulations. This warning applies to the specific UK 5 mg tablet formulation, which contains 63.50 mg of lactose monohydrate per tablet. It should not be generalized to all levocetirizine tablets or oral solutions.  [1] [2] [3] 

     

Warnings & Precautions
  • - Renal Impairment: Levocetirizine is primarily eliminated through the kidneys. Patients with impaired renal function may have increased drug exposure and a higher risk of adverse reactions. Adjust the dosage according to creatinine clearance (CrCl) in adults and adolescents aged 12 years and older. Levocetirizine is contraindicated in children aged 6 months–11 years with renal impairment and in patients with end-stage renal disease or undergoing hemodialysis under the US prescribing information. [1] [2] [3] 

    - CNS Effects: Somnolence, fatigue, and asthenia may occur during treatment. Somnolence is a documented adverse reaction and should not be described as rare. Patients should exercise caution when driving, operating machinery, or performing activities requiring mental alertness and motor coordination.[1] [2] [3] 

    - Alcohol and CNS Depressants: Concurrent use with alcohol or other central nervous system depressants should be avoided because it may cause additional reductions in alertness and impair CNS performance.[1] [2] [3] 

    - Behavioral and Sleep Effects (Pediatrics): Sleep disorders have been reported in pediatric clinical studies. Post-marketing reports also include aggression, agitation, insomnia, nightmares, and other psychiatric reactions, although their frequency is unknown and a specific association with young children has not been established. Monitor for unusual behavioral or sleep changes during treatment. Agitation and restlessness have also been reported in children following overdose. [1] [3] 

     

Side Effects

The adverse effects of levocetirizine vary by age, dose, and formulation. Clinical-trial findings and post-marketing reports should be distinguished because the frequency of some reported reactions cannot be reliably estimated.[1] [2] [3] 

Common Adverse Effects 

  • Central Nervous System: Somnolence, headache, and fatigue. 

  • Gastrointestinal: Dry mouth. 

  • Respiratory: Nasopharyngitis and pharyngitis. Cough has also been reported in pediatric clinical trials. 

In adult and adolescent clinical trials, somnolence occurred in approximately 5–6%, fatigue in up to 4%, dry mouth in 2–3%, and nasopharyngitis in 4–6% of patients. [1, 2, 3] 

  

Access Data FDA+1 

  

Uncommon Adverse Effects 

  • Gastrointestinal: Abdominal pain. 

  • General Disorders: Asthenia (physical weakness). 

These reactions were classified as uncommon in the UK Summary of Product Characteristics.  [3] 

  

10887 

  

Serious Adverse Effects and Post-Marketing Reports (Frequency Not Known) 

  • Hypersensitivity Reactions: Hypersensitivity, including anaphylaxis, angioedema, rash, and urticaria. 

  • Neurological: Seizures, including febrile seizures, tremor, and movement disorders. 

  • Psychiatric and Behavioral: Aggression, agitation, hallucinations, depression, insomnia, nightmares, and suicidal ideation. 

  • Other Reported Effects: Dizziness, nausea, vomiting, urinary retention, and visual disturbances. 

These reactions have been identified through post-marketing surveillance. Their frequency cannot be reliably estimated, and a causal relationship with levocetirizine has not been established for every reported reaction.[1] [2] [3] 

  

 

 

Drug Interactions
  • - Alcohol and CNS Depressants: Concurrent use of levocetirizine with alcohol or other central nervous system (CNS) depressants may cause additional reductions in alertness and impair psychomotor performance. The US FDA prescribing information advises avoiding concurrent use, particularly because of the risk of somnolence and impaired mental alertness.[1] [2] [3] 

    - Theophylline (400 mg once daily): A multiple-dose interaction study involving racemic cetirizine demonstrated an approximately 16% reduction in cetirizine clearance during concomitant theophylline administration. Higher theophylline doses may produce a greater effect. However, this interaction has not been directly established for levocetirizine. [1] [2] [3] 

    - Ritonavir: In a pharmacokinetic study involving racemic cetirizine, ritonavir increased cetirizine plasma AUC by approximately 42%, increased its elimination half-life by 53%, and decreased its clearance by 29%. A similar interaction with levocetirizine cannot be confirmed because direct interaction studies have not been performed. Its clinical significance for levocetirizine remains uncertain. [1] [2] [3] 

    - CYP450 Enzyme Interactions: Levocetirizine undergoes minimal hepatic metabolism. In vitro findings indicate that it is unlikely to cause significant pharmacokinetic interactions through inhibition or induction of hepatic drug-metabolizing enzymes. However, no in vivo drug interaction studies have been conducted specifically with levocetirizine, including studies involving CYP3A4 inducers. [1] [2] [3] 

     

Recent Updates or Guidelines
  • - Pediatric Use and Age Approval: The US FDA prescribing information supports levocetirizine use from 6 months of age for specific indications, not for all allergic conditions. The approved age ranges are: 

    • Perennial Allergic Rhinitis: 6 months–2 years. 

    • Chronic Idiopathic Urticaria: 6 months and older, with age-specific dosing. 

    Pediatric use is supported by the US prescribing information, with dosing based on the indication and age. The UK 5 mg tablet SmPC has different age restrictions and recommends its tablet formulation for children aged 6 years and above. [1] [3]  

    - Clinical Guidelines (2024–2026): Updated international guidelines support second-generation H₁ antihistamines as first-line symptomatic treatment for chronic urticaria. Levocetirizine is among the agents with supporting clinical evidence. [7] 

    The ARIA-EAACI 2024–2025 allergic rhinitis guideline supports second-generation oral antihistamines over leukotriene receptor antagonists for allergic rhinitis. Levocetirizine has demonstrated efficacy, particularly in perennial allergic rhinitis. However, intranasal corticosteroids are preferred over oral antihistamines when comparing these treatment routes. The guideline does not recommend levocetirizine specifically over other second-generation antihistamines. [8] 

    - Long-Term Pediatric Safety: The UK product information reports an 18-month clinical trial involving 255 levocetirizine-treated children with atopic conditions, aged 12–24 months at study entry. The reported safety profile was similar to that observed in short-term studies involving children aged 1–5 years. These findings provide supportive long-term pediatric safety evidence, but should not be interpreted as definitive proof of safety in every pediatric population or indication. [3] 

     

Storage Conditions
  • - Storage Temperature: Store levocetirizine tablets and oral solution at 20°C to 25°C (68°F to 77°F). Temperature excursions between 15°C and 30°C (59°F to 86°F) are permitted under the US FDA prescribing information. [1] 

    - Tablets: Store at the recommended room temperature. The US DailyMed labeling specifies dispensing tablets in a tight, light-resistant container with a child-resistant closure, where required. [2] 

    - Protection from Light and Moisture: Follow the specific product packaging instructions. The cited US generic tablet label specifies a tight, light-resistant container. The UK SmPC for the cited blister-packed tablet states that no special storage precautions are required. [2] [3] 

    - Oral Solution: Follow the manufacturer's storage instructions and retain the medicine in its original container. The established references do not specify a universal requirement to avoid freezing or a fixed discard period after opening. [1] 

     

Available Brand Names
বাংলায় দেখুন